CN106214966A - One is thrombocytopenic Chinese medicine composition after treating chemotherapy - Google Patents
One is thrombocytopenic Chinese medicine composition after treating chemotherapy Download PDFInfo
- Publication number
- CN106214966A CN106214966A CN201610249503.1A CN201610249503A CN106214966A CN 106214966 A CN106214966 A CN 106214966A CN 201610249503 A CN201610249503 A CN 201610249503A CN 106214966 A CN106214966 A CN 106214966A
- Authority
- CN
- China
- Prior art keywords
- parts
- effect
- chinese medicine
- treatment
- chemotherapy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/898—Orchidaceae (Orchid family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/32—Bones; Osteocytes; Osteoblasts; Tendons; Tenocytes; Teeth; Odontoblasts; Cartilage; Chondrocytes; Synovial membrane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/36—Skin; Hair; Nails; Sebaceous glands; Cerumen; Epidermis; Epithelial cells; Keratinocytes; Langerhans cells; Ectodermal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/481—Astragalus (milkvetch)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/70—Polygonaceae (Buckwheat family), e.g. spineflower or dock
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/70—Polygonaceae (Buckwheat family), e.g. spineflower or dock
- A61K36/704—Polygonum, e.g. knotweed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biotechnology (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Botany (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Cell Biology (AREA)
- Biomedical Technology (AREA)
- Developmental Biology & Embryology (AREA)
- Immunology (AREA)
- Virology (AREA)
- Zoology (AREA)
- Dermatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The invention discloses thrombocytopenic Chinese medicine composition after one treats chemotherapy, relate to Chinese medicine and pharmacy field, be made up of the pharmacodynamic raw materials of following weight parts: Radix Astragali Preparata 20 ~ 30 parts, Colla Corii Asini 10 ~ 20 parts, Herba pyrolae japonicae 20 ~ 30 parts, Herba Agrimoniae 20 ~ 30 parts, Cornu Bubali 20 ~ 30 parts, Radix Rumicis Crispi 9 ~ 15 parts, Testa arachidis hypogaeae 3 ~ 5 parts.In prescription of the present invention, seven flavor medicine effect raw material is easy to get, moderate, disclosure satisfy that the level of consumption of most of sufferer, sufferer treatment hematologic disease both expensive, this prescription medicine as auxiliary treatment, there is reinforcing spleen and kidney, effect of benefiting qi and nourishing blood hemostasis, based on treatment must aim at the pathogenesis of disease, treating both the principal and secondary aspects of a disease, realization takes stopgap measures and takes into account with effecting a permanent cure, and has the effect promoting platelet, reducing bleeding episode generation, and curative effect is reliable, cheap, having no side effect, clinical application effect is notable, greatly alleviates the financial burden of patient.
Description
Technical field
The present invention relates to Chinese medicine and pharmacy field, thrombocytopenic Chinese medicine composition after specifically one treats chemotherapy
Thing.
Background technology
Malignant hematologic disease (leukemia, lymphoma and multiple myeloma etc.) is the modal disease of hematology, and chemotherapy is
Very important treatment means.Its major side effects is bone marrow depression, and wherein thrombocytopenia is that ratio is more serious and difficult
Problem, the lighter may result in Gingival blood oozing, skin mucosa ecchymosis, and severe one can cause digestive tract, urogenital tract and intracranial hemorrhage
Etc. jeopardizing patient vitals.At present clinical treatment is based on platelet transfusion, but because the holding time is short, blood source lacks, spend relatively
High, it may occur however that Hematogenous infection, transfusion reaction and invalid infusion etc., clinical practice is restricted；Other thrombocytosis
Medicine such as interleukin 11 (IL-11), RhTPPO RHTPO (TPO), expensive, use cannot be popularized.Along with China
The development of Traditional Chinese Medicine medical science, the clinical effectiveness for the treatment of by Chinese herbs chemotherapy-induced thrombocytopenia is continuously available the affirmative of scholar.Send out
A person of good sense through for many years practice be found that one treat chemotherapy after thrombocytopenic Chinese medicine composition, blood after chemotherapy can be effectively improved
Platelet reduces the symptoms such as hemorrhage, the spiritlessness and weakness that causes, dizziness, extremity are aching and limp, has lifting platelet, reduces bleeding episode and send out
Raw, curative effect is reliable, cheap, the advantage that has no side effect, clinical effectiveness is notable.
Summary of the invention
For solving the technical problem of above-mentioned existence, the invention provides thrombocytopenic Chinese drug-treated group after one treats chemotherapy
Compound, promotes platelet, reduces bleeding episode and occurs, and curative effect is reliable, cheap, has no side effect.
For reaching above-mentioned purpose, the technical solution adopted in the present invention is:
One is thrombocytopenic Chinese medicine composition after treating chemotherapy, is made up of the pharmacodynamic raw materials of following weight parts:
Radix Astragali Preparata 20 ~ 30 parts, Colla Corii Asini 10 ~ 20 parts, Herba pyrolae japonicae 20 ~ 30 parts, Herba Agrimoniae 20 ~ 30 parts, Cornu Bubali 20 ~ 30 parts, sheep
Hoof root 9 ~ 15 parts, Testa arachidis hypogaeae 3 ~ 5 parts.
As preferably, this Chinese medicine composition is made up of the pharmacodynamic raw materials of following weight parts: Radix Astragali Preparata 25 parts, Colla Corii Asini 15
Part, Herba pyrolae japonicae 25 parts, Herba Agrimoniae 25 parts, Cornu Bubali 25 parts, Radix Rumicis Crispi 12 parts, Testa arachidis hypogaeae 4 parts.
The pharmacological effect of each crude drug of the present invention is:
Radix Astragali Preparata: sweet, tepor；Return lung, spleen, liver, kidney channel；Benefiting QI for strengthening the superficies, arresting sweating takes off admittedly, holds in the palm skin ulcer granulation promoting, inducing diuresis to remove edema；For gas
Empty weak, sinking of QI of middle-JIAO, chronic diarrhea proctoptosis, metrorrhagia of having blood in stool, exterior deficiency spontaneous perspiration, carbuncle difficulty is burst, and bursts for a long time and does not holds back, and blood deficiency and yellow complexion, interior-heat disappears
Thirsty etc..The excellent kind QI invigorating invigorating middle warmer of Radix Astragali Preparata.
Colla Corii Asini: sweet is flat；Return lung, liver, kidney channel；Tonifying blood and arresting bleeding is nourshing Yin and drynsessmoistening prescription；For blood deficiency and yellow complexion, dizziness cardiopalmus, the heart
Tired sleeplessness, xeropulmonary cough.
Herba pyrolae japonicae: sweet, bitter, temperature；Return lung meridian, stomach warp, Liver Channel, kidney channel；Qi-restoratives kidney tonifying, expelling wind and removing dampness, strengthening the tendons and bones, only
Cough, hemostasis；For lumbago due to renal deficiency, rheumatic arthralgia, muscles and bones flaccidity is soft, and new chronic cough is coughed, and spits blood, epistaxis, metrorrhagia, traumatic hemorrhage.
Herba Agrimoniae: bitter, puckery is flat；GUIXIN, Liver Channel；Astringing to arrest bleeding, preventing the attack (or recurrence) of malaria, dysentery relieving, removing toxic substances.For hemoptysis, spit blood, metrorrhagia
Hematochezia, malaria, dysentery, de-power impairment caused by overstrain, carbuncle sore tumefacting virus, pudendal pruritus leukorrhagia.
Cornu Bubali: bitter, cold；GUIXIN, Liver Channel；Clearing away heat and cooling blood, removing toxic substances, arresting convulsion；For epidemic febrile disease high heat, unconsciousness and delirium, send out speckle
Dermexanthesis, hematemesis and epistaxis, infantile convulsion, demented.
Radix Rumicis Crispi: bitter, sour, cold；Heat-clearing and toxic substances removing, hemostasis, relieving constipation, parasite killing；For epistaxis, hematohidrosis, disintegration, big constipation
Knot, has blood in stool.
Testa arachidis hypogaeae: sweet, puckery is flat；Return lung, spleen, Liver Channel；Tonifying blood and arresting bleeding；Hemorrhage for syndrome of deficiency of blood and the deficiency of vital energy.
After chemotherapy, thrombocytopenic main pathogenesis characteristics is that chemotherapeutics damages spleen kidney, essence and blood biochemistry unrooted, QI and blood
Raw passive, failing of the spleen to transport, QI failing to control blood, blood circulating away from normal passage and excessive, thus subcutaneous even visceral hemorrhage occurs, treatment when with
The hemostasis of reinforcing spleen and kidney, benefiting qi and nourishing blood is main.
Radix Astragali Preparata in the present invention, Colla Corii Asini, two medicines share has reinforcing spleen and kidney, the merit of benefiting qi and nourishing blood hemostasis, mainly uses
Thrombocytopenia and deficiency of qi and blood after treatment chemotherapy, this disease is risen, with invigorating spleen and kidney, QI invigorating in treatment because of chemotherapy damage spleen kidney
It is main for nourishing blood, and Colla Corii Asini also has hemostasia effect simultaneously, embodies the basic rule for the treatment of of the traditional Chinese medical science " treating both the principal and secondary aspects of a disease ", is also the original of we
Part, is monarch drug altogether；Herba pyrolae japonicae, Herba Agrimoniae, two medicines share qi-restoratives kidney tonifying, nourishing blood and hemoslasis, strengthen the power of monarch drug, are ministerial drug altogether；
Cornu Bubali, Radix Rumicis Crispi, two medicines share cooling blood for hemostasis, for preventing hemorrhage effect from highlighting, are adjuvant drug altogether；Testa arachidis hypogaeae is only enriched blood
Blood, can strengthen effect of monarch-minister drug, for making medicine；The cooperation of above 7 taste Chinese medicines, plays reinforcing spleen and kidney, the work of benefiting qi and nourishing blood hemostasis
With.
In sum, in prescription of the present invention, seven flavor medicine effect raw material is easy to get, moderate, it is possible to meet disappearing of most of sufferer
Water wasting put down, sufferer treatment hematologic disease both expensive, as auxiliary treatment this prescription medicine, have reinforcing spleen and kidney, QI invigorating support
Effect of blood hemostasis, based on treatment must aim at the pathogenesis of disease, treating both the principal and secondary aspects of a disease, it is achieved take stopgap measures and take into account with effecting a permanent cure, has lifting platelet, reduces
Effect that blood event occurs, curative effect is reliable, cheap, has no side effect, and clinical application effect is notable, greatly alleviates patient
Financial burden.
Detailed description of the invention
Describe the present invention below in conjunction with specific embodiment:
Thrombocytopenic Chinese medicine composition after this treatment chemotherapy, is made up of the pharmacodynamic raw materials of following weight parts:
Radix Astragali Preparata 20 ~ 30 parts, Colla Corii Asini 10 ~ 20 parts, Herba pyrolae japonicae 20 ~ 30 parts, Herba Agrimoniae 20 ~ 30 parts, Cornu Bubali 20 ~ 30 parts, sheep
Hoof root 9 ~ 15 parts, Testa arachidis hypogaeae 3 ~ 5 parts.
As preferably, this Chinese medicine composition is made up of the pharmacodynamic raw materials of following weight parts: Radix Astragali Preparata 25 parts, Colla Corii Asini 15
Part, Herba pyrolae japonicae 25 parts, Herba Agrimoniae 25 parts, Cornu Bubali 25 parts, Radix Rumicis Crispi 12 parts, Testa arachidis hypogaeae 4 parts.
Above-mentioned Chinese medicine composition can be made as decoction, powder, pill, unguentum, syrup, tablet, granule or powder preparation to be taken after being infused in boiling water, granule
Agent, capsule.
Described pill can be honeyed pill, the watered pill, paste pill or concentrated pill, and described unguentum can be fluid extract, extractum or soft extracts
Agent.
The decoction of described decoction is: in addition to Colla Corii Asini, Cornu Bubali, adds water 10ml by every 1g medicine, calculates total water requirement.
First decocts (without Colla Corii Asini, Cornu Bubali) adds the 70% of total Water, soaks 30 minutes, boils rear slow fire boiling 20 minutes, filter
Go out medicine juice 300ml；Second decocts (without Colla Corii Asini, Cornu Bubali) adds remaining 30%, boils rear slow fire and decocts 15 minutes again, leaches
Medicine juice 200ml；Leach medicine juice blending for twice uniformly；Cornu Bubali adds water 10ml by every 1g medicine, calculates after total water requirement once
Property adding enough water amount, decoct medicine juice 100ml, be blended in front twice medicine juice, altogether 600ml.
Instructions of taking: the Chinese herbs decoction of good mixing will be decocted, point 2 decoction being taken warmly of morning and evening.1/2 dose of Colla Corii Asini is taken when each taking
Amount adds molten in medicine juice.Potion on the one, 3-4 week is a course for the treatment of, determines, according to chemotherapy treatment, the course for the treatment of of taking medicine.Diet during taking medicine
Greasy, raw and cold and maror, harmonizing emotions, note warming.
Embodiment 1: measure Radix Astragali Preparata 20g, Colla Corii Asini 20 g, Herba pyrolae japonicae 20 g, Herba Agrimoniae 30 g, Cornu Bubali 20 g, sheep
Hoof root 15 g, Testa arachidis hypogaeae 3 g, be fabricated to honeyed pill.
Embodiment 2:
Measure Radix Astragali Preparata 30g, Colla Corii Asini 10g, Herba pyrolae japonicae 30 g, Herba Agrimoniae 20 g, Cornu Bubali 30 g, Radix Rumicis Crispi 9g, Semen arachidis hypogaeae red
Clothing 5 g, is fabricated to unguentum.
Embodiment 3:
Measure Radix Astragali Preparata 25g, Colla Corii Asini 15 g, Herba pyrolae japonicae 25 g, Herba Agrimoniae 25 g, Cornu Bubali 25g, Radix Rumicis Crispi 12g, Semen arachidis hypogaeae red
Clothing 4 g, is fabricated to decoction.
Embodiment 4:
Measure Radix Astragali Preparata 20g, Colla Corii Asini 15 g, Herba pyrolae japonicae 20 g, Herba Agrimoniae 25 g, Cornu Bubali 28g, Radix Rumicis Crispi 10 g, Semen arachidis hypogaeae
Scarlet 3g, is fabricated to powder.
Embodiment 5:
Measure Radix Astragali Preparata 22g, Colla Corii Asini 16g, Herba pyrolae japonicae 22g, Herba Agrimoniae 23 g, Cornu Bubali 25g, Radix Rumicis Crispi 13g, Testa arachidis hypogaeae
4g, is fabricated to the watered pill.
Embodiment 6:
Measure Radix Astragali Preparata 26g, Colla Corii Asini 18g, Herba pyrolae japonicae 26g, Herba Agrimoniae 22g, Cornu Bubali 22g, Radix Rumicis Crispi 14g, Testa arachidis hypogaeae 3
G, is fabricated to concentrated pill.
Embodiment 7:
Measure Radix Astragali Preparata 28g, Colla Corii Asini 12 g, Herba pyrolae japonicae 28g, Herba Agrimoniae 20g, Cornu Bubali 23g, Radix Rumicis Crispi 12g, Testa arachidis hypogaeae
4.5g, is fabricated to syrup.
Clinical model case:
Clinical case 1: Lee so-and-so, man, 57 years old, because " weak 1 week, skin is dispersed in petechia 4 days " is admitted to hospital.Before 1 week, patient is conscious
Weak, activity postemphasis；Companion's dizziness, sometimes has palpitation, breathes hard, do not do diagnosis and treatment；The skin that stumbled on before 4 days is dispersed in petechia,
Without epistaxis, gingiva bleeding gingival hemorrhage, without hematemesis, spitting of blood；Nothing is had blood in stool, gross hematuria, comes institute and goes to a doctor.Previously body is good for.Have a medical check-up: anemia looks,
Trunk, limbs skin is dispersed in petechia, and superficial lymph knot does not touches great, and the light tenderness of breastbone, liver spleen is little.Laboratory is examined
Look into: peripheral blood: leukocyte WBC:21.3 × 109/L, Hb H b:77g/L, platelet PLT:38 × 1012/L, after being admitted to hospital
Improve medullary cell, immunology, molecular biology, cytogenetics etc. to check.It is diagnosed as acute myeloid leukemia (M2).Give
With DA scheme chemotherapy, end of chemotherapy PLT is down to 13 × 1012/L, and patient starts epistaxis, gingiva bleeding gingival hemorrhage occur, starts to take this
Invention medicine every day one pair, early, evening takes.After taking seven, platelet rises to 22 × 1012/L, and bleeding substantially alleviates.
Continuing to take medicine 2 weeks, platelet rises to 76 × 1012/L, carries out successive treatment.
Clinical case 2: Zhang, female, 61 years old, " finding Diagnosis of Cervical Masses 2 weeks " was admitted to hospital.Stumbled on before 2 weeks left neck
Enclosed mass, i.e. carrys out hospital admission, shows to checking with color ultrasound etc.: the multiple enlarged lymph node of left neck, however not excluded that lymphoma may.Both
Toward healthy.Have a medical check-up: the accessible many pieces of enlarged lymph nodes of left neck, big person such as Fructus Jujubae, little person such as Semen arachidis hypogaeae size, matter is harder, relatively
Fixing, without touching a tender spot.Improve routine blood test, lymph node biopsy, bone marrow smear etc. after being admitted to hospital to check, make a definite diagnosis: diffusivity large B cell lymph
Tumor.Giving and Mabthera+CHOP chemotherapy, after one week, platelet is down to 28 × 1012/L, starts to take medicine of the present invention every day one pair,
Early, taking evening, after one week, platelet rises to 41 platelet and rises to, and continues to take medicine 2 weeks, and platelet rises to 109 × 1012/L, carries out
Next course for the treatment of chemotherapy.
Clinical case 3: grandson so-and-so, man, 77 years old, because " flank pain discomfort March " goes to a doctor.First patient goes to a doctor in my institute's bone
Section's outpatient service, lumbar vertebra MRI checks and shows: the multiple sample bone resorption infringement of giving a farfetched interpretation of lumbosacral spine bone, it is considered to multiple myeloma.Go to hematology,
It is diagnosed as after improving coherence check: multiple myeloma.Giving and VAD scheme chemotherapy, after 4 days, platelet is down to 33 × 1012/L,
There is petechia in double skin of upper extremity.Immediately begin to take medicine of the present invention every day one pair, early, evening take, platelet liter after 10 days
To 47 × 1012/L, bleeding disappears, continues to take medicine 3 weeks, and platelet rises to normally, carry out chemotherapy again.
Certainly, described above is not limitation of the present invention, and the present invention is also not limited to the example above, and this technology is led
Change that the technical staff in territory is made in the essential scope of the present invention, retrofit, add or replace, also should belong to the present invention's
Protection domain.
Claims (2)
1. thrombocytopenic Chinese medicine composition after a treatment chemotherapy, it is characterised in that by the pharmacodynamic raw materials of following weight parts
Composition:
Radix Astragali Preparata 20 ~ 30 parts, Colla Corii Asini 10 ~ 20 parts, Herba pyrolae japonicae 20 ~ 30 parts, Herba Agrimoniae 20 ~ 30 parts, Cornu Bubali 20 ~ 30 parts, sheep
Hoof root 9 ~ 15 parts, Testa arachidis hypogaeae 3 ~ 5 parts.
One the most according to claim 1 is thrombocytopenic Chinese medicine composition after treating chemotherapy, it is characterised in that under by
The pharmacodynamic raw materials stating weight portion forms: Radix Astragali Preparata 25 parts, Colla Corii Asini 15 parts, Herba pyrolae japonicae 25 parts, Herba Agrimoniae 25 parts, Cornu Bubali 25
Part, Radix Rumicis Crispi 12 parts, Testa arachidis hypogaeae 4 parts.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610249503.1A CN106214966A (en) | 2016-04-21 | 2016-04-21 | One is thrombocytopenic Chinese medicine composition after treating chemotherapy |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610249503.1A CN106214966A (en) | 2016-04-21 | 2016-04-21 | One is thrombocytopenic Chinese medicine composition after treating chemotherapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN106214966A true CN106214966A (en) | 2016-12-14 |
Family
ID=57518943
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610249503.1A Pending CN106214966A (en) | 2016-04-21 | 2016-04-21 | One is thrombocytopenic Chinese medicine composition after treating chemotherapy |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106214966A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112998257A (en) * | 2021-03-29 | 2021-06-22 | 戴清桂 | Dietetic therapy composition and preparation method thereof |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101406539A (en) * | 2008-11-25 | 2009-04-15 | 王希胜 | Medicament for treating thrombocytopenia after chemotherapy |
| CN101513504A (en) * | 2009-03-24 | 2009-08-26 | 李�杰 | Chinese herbal medicine for remedying thrombocytopenia after radiochemotherapy |
| CN102188592A (en) * | 2011-06-13 | 2011-09-21 | 山西振东开元制药有限公司 | Medicine for treating thrombocytopenia after tumor chemotherapy and preparation method thereof |
| CN102205051A (en) * | 2011-05-20 | 2011-10-05 | 韩丹艳 | Notoginseng root hematogenic medicament and preparation method thereof |
| CN102335294A (en) * | 2011-09-22 | 2012-02-01 | 李宗宪 | Chinese medicinal herb decoction for treating thrombocytopenia after radio-chemotherapy |
| CN103405542A (en) * | 2013-09-10 | 2013-11-27 | 河南中医学院 | Traditional Chinese medicine for treating leucopenia after chemotherapy |
-
2016
- 2016-04-21 CN CN201610249503.1A patent/CN106214966A/en active Pending
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101406539A (en) * | 2008-11-25 | 2009-04-15 | 王希胜 | Medicament for treating thrombocytopenia after chemotherapy |
| CN101513504A (en) * | 2009-03-24 | 2009-08-26 | 李�杰 | Chinese herbal medicine for remedying thrombocytopenia after radiochemotherapy |
| CN102205051A (en) * | 2011-05-20 | 2011-10-05 | 韩丹艳 | Notoginseng root hematogenic medicament and preparation method thereof |
| CN102188592A (en) * | 2011-06-13 | 2011-09-21 | 山西振东开元制药有限公司 | Medicine for treating thrombocytopenia after tumor chemotherapy and preparation method thereof |
| CN102335294A (en) * | 2011-09-22 | 2012-02-01 | 李宗宪 | Chinese medicinal herb decoction for treating thrombocytopenia after radio-chemotherapy |
| CN103405542A (en) * | 2013-09-10 | 2013-11-27 | 河南中医学院 | Traditional Chinese medicine for treating leucopenia after chemotherapy |
Non-Patent Citations (1)
| Title |
|---|
| 张蓓等: "升板方治疗肿瘤化疗后血小板减少症的临床观察", 《广东医学》 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112998257A (en) * | 2021-03-29 | 2021-06-22 | 戴清桂 | Dietetic therapy composition and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102526326B (en) | Traditional Chinese medicine for treating postmenopausal osteoporosis and preparation method thereof | |
| CN102698227A (en) | Chinese medicine for treating constipation | |
| CN103566346B (en) | A kind of medicine and preparation method for the treatment of person in middle and old age's abdominal distention | |
| CN104189811A (en) | Traditional Chinese medicine composition for treating postpartum fainting and preparation method thereof | |
| CN102188638A (en) | Medicament for treating liver cancer | |
| CN108079250A (en) | A kind of herbal composite for treating the proliferation of mammary gland | |
| CN102139051B (en) | Application of soft capsule capable of clearing heat and eliminating toxin in preparation of medicament for treating viral pneumonia | |
| CN103585449B (en) | For treating migrainous Chinese medicine composition | |
| CN102579610A (en) | Chinese medicinal composition for treating cerebral hemorrhage and preparation method thereof | |
| CN105616655A (en) | Medicinal and edible composition applicable to stagnant blood constitution | |
| CN106214966A (en) | One is thrombocytopenic Chinese medicine composition after treating chemotherapy | |
| CN104435560B (en) | Alleviate the Chinese medicine composition and preparation method of incision pain after anesthesia disappears | |
| CN105497262A (en) | Medicine composition for treating liver-yin and kidney-yin deficiency type polycystic ovarian syndrome | |
| CN101543533A (en) | Medicament for treating leukemia | |
| CN104840902A (en) | Traditional Chinese medicine preparation for treating ovarian tumor | |
| CN103705857B (en) | For preventing the Chinese medicine composition of oral cavity radiomucitis | |
| CN104117018A (en) | Traditional Chinese medicine composition for treating coronary heart disease | |
| CN103690902B (en) | For preventing the Chinese medicine preparation of nasopharyngeal carcinoma radiation side reaction | |
| CN103705856B (en) | For preventing the Chinese medicine composition of chemicotherapy acute radio-reaction | |
| CN103301281B (en) | Traditional Chinese medicine for treating uterine fibroid and preparation method thereof | |
| CN103007193B (en) | Chinese medicinal composition for treating gallbladder distention | |
| CN105943753A (en) | Traditional Chinese medicinal composition for preventing and treating chronic fatigue syndrome | |
| CN105853603A (en) | Yao medicine composition for treating insomnia and preparation method thereof | |
| CN105233075A (en) | Traditional Chinese medicine combination treating coronary heart disease | |
| CN104645224A (en) | Traditional Chinese medicine preparation for treating costal chondritis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20161214 |